{'fraction_non_alphanumeric': 0.041742286751361164, 'fraction_numerical': 0.021778584392014518, 'mean_word_length': 6.116129032258065, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Combined cytoreductive surgery and intraoperative hyperthermic chemo-perfusion for peritoneal carcinomatosis: methods, postoperative features and end results].

Peritoneal carcinomatosis is detected in 10-40% of patients with "first look" peritoneal tumors. Median survival after chemotherapy is generally 2-6 months. Use of cytoreductive surgery and intraoperative intraperitoneal chemohyperthermic perfusion (ISHTP) improves the end results significantly. The study included 45 cases of surgery: gastric cancer (15), ovarian and cervical carcinoma ('17), colorectal cancer (8) and miscellaneous cancers involving advanced peritoneal carcinomatosis (5). ISHTP procedure was carried out immediately after cytoreductive surgery including peritonectomy (Sugarbaker). Postoperative complication and lethality frequency was 37.7 and 22.2%, respectively; mean survival--17 months. Eight patients have survived without signs of relapse; three of them--for more than 2 years. Cytoreductive surgery plus ISHTP protocol for peritoneal carcinomatosis increases survival time 3-fold and improves quality of life.